The AmplideX® suite of products is designed to solve unmet testing needs in inherited genetic disorders. The technology overcame a 20-year challenge by reliably amplifying the FMR1 gene. It allowed researchers to gain a deeper understanding of fragile X syndrome, the most common known inherited cause of intellectual disability and autism. Asuragen has also pioneered innovation in other major areas.

The Asuragen Oncology portfolio uses proprietary molecular chemistry and informatics solutions to deliver critical clinical research insights that drive the evolution of therapy, patient monitoring and precision medicine. The QuantideX® suite of products employs molecular methods ranging from qPCR to NGS to help advance our understanding of cancer. Our approach is to selectively deploy the right technology for the right result.

Asuragen provides high quality, custom molecular diagnostics (MolecularDx) controls by leveraging a combination of product development and manufacturing expertise. Our suite of custom products includes Armored RNA^®, Armored RNA Quant^®, Armored DNA Quant™, plasmid DNA (circular and linearized) and in vitro transcribed RNA, providing unique, target-specific controls to meet your needs.

Armored Controls have been utilized in IVD-approved assays for more than 20 years and continue to serve as an important tool in the rapidly evolving space of molecular diagnostics.